Skip to content
Open access

Comparative Adverse Event Reporting Patterns of Amoxicillin and Amoxicillin/Clavulanic Acid in FAERS: A 2022–2025 Disproportionality Analysis

Oct 2026 · Health Science Reports · Vol 9 · 0 citations · 29 references
Medicine

Abstract

Amoxicillin, alone or combined with clavulanic acid, is widely used for the treatment of bacterial infections. While clavulanic acid expands amoxicillin's antibacterial spectrum by inhibiting β‐lactamases, differences in their real‐world safety profiles and reporting patterns remain relevant for pharmacovigilance and antimicrobial surveillance. This study aimed to characterize and compare adverse event reporting associated with amoxicillin and amoxicillin/clavulanic acid and to explore reporting signals involving Preferred Terms potentially associated with reduced treatment effectiveness.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.